bioMérieux Acquires Specific Diagnostics
April 12, 2022
bioMérieux has agreed to acquire Specific Diagnostics, a U.S.-based developer of the SPECIFIC REVEAL Rapid AST system, to strengthen its sepsis and antimicrobial stewardship portfolio. bioMérieux will acquire 100% of Specific Diagnostics for a consideration equivalent to 3.3% of bioMérieux's market capitalization as of April 11, 2022, paid in cash and newly issued shares; the deal was expected to close by the end of Q2 2022 subject to regulatory approvals.
- Buyers
- bioMérieux
- Targets
- Specific Diagnostics
- Industry
- Medical Devices
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
R-Biopharm AG Acquires AusDiagnostics
June 7, 2022
Biotechnology
German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.
-
US BioTek Laboratories Acquires RealTime Laboratories
March 19, 2024
Healthcare Services
US BioTek Laboratories, a Pike Street Capital portfolio company, has acquired Dallas-based RealTime Laboratories to expand its diagnostic testing capabilities, specifically mycotoxin and infectious disease testing. The deal broadens the combined organization’s services and geographic footprint while both labs continue operating at their respective locations.
-
Microbiologics Acquires SensID to Expand Diagnostic Reference Materials Portfolio
November 6, 2024
Biotechnology
Microbiologics has acquired SensID, a Rostock, Germany-based maker of reference materials and quality controls for molecular diagnostics, marking Microbiologics' first location outside the United States. The deal expands Microbiologics' capabilities into oncology and precision medicine and combines both companies' expertise to broaden diagnostic quality-control offerings for diagnostic developers and clinical labs.
-
Biosynex S.A. Acquires ProciseDx Inc.
June 13, 2023
Medical Devices
French diagnostics company Biosynex S.A. has acquired ProciseDx Inc., a U.S.-based point-of-care in vitro diagnostics company. The acquisition will help Biosynex commercialize ProciseDx's therapeutic drug monitoring (TDM) tests for infliximab and adalimumab in the United States and accelerate point-of-care biologic drug monitoring.
-
Sherlock Biosciences Acquires Sense Biodetection
February 1, 2023
Biotechnology
Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.
-
Exact Sciences Acquires Paradigm Diagnostics and Viomics
March 3, 2020
Healthcare Services
Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.